Federated Investors Inc Decreased Corcept Therapeutics Inc (NASDAQ:CORT) Stake By $11.50 Million

August 12, 2018 - By Jason Dias

Corcept Therapeutics Incorporated (NASDAQ:CORT) LogoInvestors sentiment decreased to 1.28 in Q1 2018. Its down 0.21, from 1.49 in 2017Q4. It is negative, as 28 investors sold CORT shares while 55 reduced holdings. 46 funds opened positions while 60 raised stakes. 84.82 million shares or 2.95% less from 87.40 million shares in 2017Q4 were reported. New York-based Amalgamated Bancorp has invested 0.01% in Corcept Therapeutics Incorporated (NASDAQ:CORT). Renaissance Tech Limited Liability Company holds 0.09% in Corcept Therapeutics Incorporated (NASDAQ:CORT) or 4.80M shares. Citigroup owns 46,655 shares. Ameriprise Fincl Inc invested in 0.01% or 850,503 shares. Bnp Paribas Arbitrage Sa stated it has 30,123 shares. California Public Employees Retirement holds 0% of its portfolio in Corcept Therapeutics Incorporated (NASDAQ:CORT) for 141,417 shares. Amer Int Incorporated invested 0% in Corcept Therapeutics Incorporated (NASDAQ:CORT). Fifth Third Bank & Trust holds 0% or 33,211 shares. Huntington Savings Bank stated it has 1,963 shares. Essex Investment Mgmt Limited Company reported 0.94% stake. Voya Investment Mngmt Lc reported 73,083 shares. Ny State Teachers Retirement Systems accumulated 68,326 shares. Group One Trading Ltd Partnership owns 19,429 shares for 0% of their portfolio. Farmers Merchants Investments Incorporated has 380 shares. 29,204 are owned by Stone Ridge Asset Mgmt Lc.

Since March 6, 2018, it had 1 insider buy, and 6 insider sales for $988,257 activity. The insider FISHMAN ROBERT S sold $125,323. BAKER G LEONARD JR also sold $480,312 worth of Corcept Therapeutics Incorporated (NASDAQ:CORT) shares.

Federated Investors Inc decreased its stake in Corcept Therapeutics Inc (NASDAQ:CORT) by 6.04% based on its latest 2018Q2 regulatory filing with the SEC. Federated Investors Inc sold 766,619 shares as the company’s stock rose 20.10% while stock markets declined. The institutional investor held 11.92 million shares of the major pharmaceuticals company at the end of 2018Q2, valued at $187.38 million, down from 12.69M at the end of the previous reported quarter. Federated Investors Inc who had been investing in Corcept Therapeutics Inc for a number of months, seems to be less bullish one the $1.53B market cap company. The stock decreased 5.15% or $0.72 during the last trading session, reaching $13.26. About 4.15M shares traded or 227.23% up from the average. Corcept Therapeutics Incorporated (NASDAQ:CORT) has risen 60.38% since August 13, 2017 and is uptrending. It has outperformed by 47.81% the S&P500.

Federated Investors Inc, which manages about $34.12B US Long portfolio, upped its stake in Grand Canyon Ed Inc (NASDAQ:LOPE) by 107,107 shares to 107,345 shares, valued at $11.98 million in 2018Q2, according to the filing. It also increased its holding in Invesco Ltd (NYSE:IVZ) by 1.53 million shares in the quarter, for a total of 2.38 million shares, and has risen its stake in Honeywell Intl Inc (NYSE:HON).

Federated Investors Inc is a Pennsylvania-based institutional investor with more than $254.00 billion AUM in March, 2014. This fund invests only a small percentage of its assets in equities and options. Federated Investors Inc is the 12th largest institutional investor in our database. Taken from Federated Investors latest Adv, the fund reported to have 93 full and part-time employees. Among which 91 performing investment advisory and research functions. The institutional investor had more than 107 clients.

Corcept Therapeutics Incorporated (NASDAQ:CORT) Ratings Coverage

Among 4 analysts covering Corcept Therapeutics Inc (NASDAQ:CORT), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Corcept Therapeutics Inc had 7 analyst reports since March 8, 2018 according to SRatingsIntel. Seaport Global initiated Corcept Therapeutics Incorporated (NASDAQ:CORT) on Friday, April 13 with “Buy” rating. The stock of Corcept Therapeutics Incorporated (NASDAQ:CORT) earned “Buy” rating by FBR Capital on Thursday, March 8. FBR Capital maintained the stock with “Buy” rating in Tuesday, March 20 report. Stifel Nicolaus downgraded the shares of CORT in report on Thursday, May 31 to “Hold” rating. On Tuesday, June 12 the stock rating was maintained by FBR Capital with “Buy”. FBR Capital maintained Corcept Therapeutics Incorporated (NASDAQ:CORT) on Tuesday, June 19 with “Buy” rating.

Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company has market cap of $1.53 billion. It offers Korlym tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It has a 11.73 P/E ratio. The firm is also developing Korlym in combination with eribulin, which is in Phase I/II clinical trial to treat patients with metastatic triple-negative breast cancer; Korlym in combination with drug Abraxane that is in Phase II clinical trial to treat patients with triple-negative breast cancer; and Korlym combined with the androgen deprivation agent enzalutamide, which is in Phase II clinical trial to treat patients with metastatic castration-resistant prostate cancer.

More notable recent Corcept Therapeutics Incorporated (NASDAQ:CORT) news were published by: Gurufocus.com which released: “3 Stocks to Sell Friday” on August 10, 2018, also Streetinsider.com with their article: “After-Hours Stock Movers 08/09: (TTD) (OSTK) (PBYI) Higher; (CORT) (XONE) (DBX) Lower (more…)” published on August 09, 2018, Nasdaq.com published: “Corcept Therapeutics Announces Second Quarter 2018 Financial Results and Stock Repurchase Program; Provides …” on August 09, 2018. More interesting news about Corcept Therapeutics Incorporated (NASDAQ:CORT) were released by: Seekingalpha.com and their article: “Should You Buy Corcept Therapeutics Before Earnings?” published on July 23, 2018 as well as Benzinga.com‘s news article titled: “7 Stocks Moving In Thursday’s After-Hours Session” with publication date: August 09, 2018.

Corcept Therapeutics Incorporated (NASDAQ:CORT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.